News coverage about NantHealth (NYSE:NH) has trended somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. NantHealth earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.9378408665448 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

A number of equities research analysts have recently weighed in on NH shares. Canaccord Genuity reaffirmed a “buy” rating and set a $6.00 price target (down previously from $8.00) on shares of NantHealth in a report on Monday, August 21st. Zacks Investment Research cut NantHealth from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. BidaskClub raised NantHealth from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th. Finally, Jefferies Group LLC lowered their price objective on shares of NantHealth from $5.50 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $8.30.

NantHealth (NH) traded down 5.70% on Monday, hitting $3.64. 118,726 shares of the company were exchanged. The stock has a 50 day moving average price of $4.23 and a 200 day moving average price of $4.23. NantHealth has a one year low of $3.59 and a one year high of $13.13. The firm’s market cap is $443.88 million.

NantHealth (NYSE:NH) last announced its earnings results on Thursday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.32). NantHealth had a negative return on equity of 83.97% and a negative net margin of 267.11%. The company had revenue of $26.23 million for the quarter, compared to analyst estimates of $31.28 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. NantHealth’s revenue for the quarter was down 16.7% on a year-over-year basis. On average, equities research analysts forecast that NantHealth will post ($0.70) EPS for the current fiscal year.

In other news, COO Ronald Allen Louks sold 26,820 shares of the company’s stock in a transaction that occurred on Friday, October 6th. The shares were sold at an average price of $4.28, for a total transaction of $114,789.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

COPYRIGHT VIOLATION WARNING: “NantHealth (NH) Earning Somewhat Favorable Media Coverage, Study Finds” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Insider Buying and Selling by Quarter for NantHealth (NYSE:NH)

Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.